ClinicalTrials.gg
CompletedNCT04015687Updated Oct 14, 2019

A Study to Evaluate the Effect of AG-881 on the Pharmacokinetics of a Single Dose of Lamotrigine in Healthy Adults

A Phase 1 interventional study of AG-881 and Lamotrigine in Healthy Participants, sponsored by Agios Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-10-14.

Sponsored by Agios Pharmaceuticals, Inc. · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Oct 2019, 7 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
22
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The main purpose of this study is to examine the effect of multiple doses of AG-881 on the pharmacokinetics (PK) of a single dose of lamotrigine in healthy adults.

02

Conditions studied

  • Healthy Participants

Keywords

  • Pharmacokinetic study
03

In context

Lead sponsor

Agios Pharmaceuticals, Inc. is the lead sponsor of 52 studies on the registry; 6 are open to participants now.

Of its 23 completed or terminated interventional studies of FDA-regulated products, 4 (17%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy, adult, male or female participants, 18-55 years of age, inclusive, at screening;
  • Continuous non-smoker who has not used nicotine-containing products for at least 3 months prior to the first dosing and throughout the study, based on participant self-reporting;
  • (BMI) ≥ 18.0 and ≤ 32.0 kilograms per square meter (kg/m\^2) at screening;
  • Medically healthy with no medical history, physical examination, laboratory profiles, vital signs or (ECG), as deemed by the principal investigator or designee;
  • Liver function tests (serum [ALT], aspartate aminotransferase [AST], alkaline phosphatase [ALP], and [total and direct]) must be ≤ the ;
  • Female participants must be of non- defined as a female who has undergone one of the following sterilization procedures at least 6 months prior to the first dosing:

    • hysteroscopic sterilization;
    • bilateral tubal ligation or bilateral salpingectomy;
    • hysterectomy;
    • bilateral oophorectomy;
    • or is with amenorrhea for at least 1 year prior to the first dosing and follicle-stimulating hormone (FSH) serum levels consistent with postmenopausal status;
  • A non-vasectomized, male participant must agree to use a condom with spermicide or abstain from sexual intercourse during the study until 90 days after the last dosing. (No restrictions are required for a vasectomized male provided his vasectomy has been performed 4 months or more prior to the first dosing of study drug. A male who has been vasectomized less than 4 months prior to study first dosing must follow the same restrictions as a non-vasectomized male);
  • If a male participant, must agree not to donate sperm from the first dosing until 90 days after the last dosing;
  • Understands the study procedures in the form (ICF), and be willing and able to comply with the protocol.

Exclusion criteria

Exclusion criteria:

  • Participant is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study;
  • History or presence of medical or psychiatric condition or disease in the opinion of the principal investigator or designee;
  • History of any illness that, in the opinion of the principal investigator or designee, might confound the results of the study or pose an additional risk to the participant (e.g., history or presence of rashes) by their participation in the study;
  • History or presence of ventricular dysfunction or risk factors for Torsades de Pointes (e.g., heart failure, hypokalemia, cardiomyopathy, family history of Long Syndrome), in the opinion of the principal investigator or designee;
  • History or presence of alcoholism or drug abuse within the past 2 years prior to the first dosing;
  • History or presence of or idiosyncratic reaction to the study drugs or related compounds;
  • Known medical history of progressive multifocal leukoencephalopathy;
  • Presence of an active skin rash;
  • Any positive responses on the Columbia-suicide severity rating scale (C-SSRS);
  • Female participants of ;
  • Female participants with a positive pregnancy test or who are lactating;
  • Positive urine drug or alcohol results at screening or first check-in;
  • Positive results at screening for (HIV) antibodies, surface antigen (HBsAg) or virus (HCV) antibodies;
  • Corrected QT interval by Fridericia (QTcF) is >450 milliseconds (msec), or Q wave, R wave, and S wave complex (QRS) interval >110 msec, or P wave to the start of the QRS complex (PR interval) >220 msec or participants who have findings deemed abnormal with clinical significance by the principal investigator or designee at screening;
  • Estimated \<90 millimeters per minute (mL/min) at screening;
  • Unable to refrain from or anticipate the use of:

    • Any drug, including prescription and non-prescription medications, herbal remedies, and vitamin supplements, beginning 14 days prior to the first dosing and throughout the study. After first dosing, ibuprofen (1.2 grams [g] per 24 hours) may be administered at the discretion of principal investigator or designee;
    • Any drugs known to be strong inducers of cytochrome P450 (CYP) 3A enzymes or uridine 5´-diphospho-glucuronyl transferases (UGTs), including St. John's Wort, for 28 days prior to the first dosing and throughout the study. Appropriate sources (e.g., Flockhart Table™) will be consulted to confirm lack of pharmacokinetic/pharmacodynamic interaction with study drug;
  • Refuses to abstain from grapefruit-containing foods or beverages or Seville orange containing foods or beverages from 14 days prior to the first dosing and throughout the study;
  • Has been on a diet incompatible with the on-study diet, in the opinion of the principal investigator or designee, within the 30 days prior to the first dosing and throughout the study;
  • Donation of blood or significant blood loss within 56 days prior to the first dose;
  • Plasma donation within 7 days prior to the first dose;
  • Participation in another clinical study within 30 days prior to the first dose. The 30-day window will be derived from the date of the last blood collection or dosing, whichever is later, in the previous study to Day 1 of the current study.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    AG-881 (Group 1)

    On Day 1 of Period 1, Group 1 participants will receive a single 50-milligram (mg) oral dose of lamotrigine at Hour 0. In Period 2, they will receive 50-mg oral doses of AG-881 once daily (QD) for 15 consecutive days (Days 1 to 15), with a single 50-mg oral dose of lamotrigine coadministered at Hour 0 on Day 14.

    Drug: AG-881 · Drug: Lamotrigine

  • Experimental
    AG-881 (Group 2)

    Following a safety and tolerability review of the data from at least 7 days of AG-881 dosing of Group 1 participants in Period 2, Group 2 participants will receive a single 50-mg oral dose of lamotrigine at Hour 0 in Period 1, and 50-mg oral doses of AG-881 QD for 15 consecutive days (Days 1 to 15), with a single 50-mg oral dose of lamotrigine coadministered at Hour 0 on Day 14 in Period 2.

    Drug: AG-881 · Drug: Lamotrigine

  • Experimental
    AG-881 (Group 3)

    Following a safety and tolerability review of the data from Group 1 participants, and from at least 7 days of AG-881 dosing of Group 2 participants in Period 2, Group 3 participants will receive a single 50-mg oral dose of lamotrigine at Hour 0 in Period 1; and 50-mg oral doses of AG-881 QD for 15 consecutive days (Days 1 to 15) with a single 50-mg oral dose of lamotrigine coadministered at Hour 0 on Day 14 in Period 2.

    Drug: AG-881 · Drug: Lamotrigine

Interventions

  • DrugAG-881

    Supplied as uncoated tablets.

  • Supplied as tablets of LAMICTAL® or generic equivalent.

    Also known as: LAMICTAL®

06

What researchers measure

Primary outcomes

  1. Area under the Concentration-time Curve from Time 0 to Infinity (AUC0-inf) for Lamotrigine Administered with Interacting Drug AG-881

    Time frame: At multiple time points daily from Day 14 to Day 21 (or early discontinuation) in Period 2 (21-day period)

  2. Area under the Concentration-time Curve from Time 0 to Infinity (AUC0-inf) for Lamotrigine Administered without Interacting Drug AG-881

    Time frame: At multiple time points daily from Day 1 to Day 8 in Period 1 (8-day period)

  3. Maximum Observed Plasma Concentration (Cmax) for Lamotrigine Administered with Interacting Drug AG-881

    Time frame: At multiple time points daily from Day 14 to Day 21 (or early discontinuation) in Period 2 (21-day period)

  4. Maximum Observed Plasma Concentration (Cmax) for Lamotrigine Administered without Interacting Drug AG-881

    Time frame: At multiple time points daily from Day 1 to Day 8 in Period 1 (8-day period)

  5. Area under the Concentration-time Curve, from Time 0 to the Last Observed Non-zero Concentration (t) (AUC0-t) for Lamotrigine Administered with Interacting Drug AG-881

    Time frame: At multiple time points daily from Day 14 to Day 21 (or early discontinuation) in Period 2 (21-day period)

  6. Area under the Concentration-time Curve, from Time 0 to the Last Observed Non-zero Concentration (t) (AUC0-t) for Lamotrigine Administered without Interacting Drug AG-881

    Time frame: At multiple time points daily from Day 1 to Day 8 in Period 1 (8-day period)

  7. Percent of AUC0-inf Extrapolated (AUC%extrap) for Lamotrigine Administered with Interacting Drug AG-881

    Time frame: At multiple time points daily from Day 14 to Day 21 (or early discontinuation) in Period 2 (21-day period)

  8. Percent of AUC0-inf Extrapolated (AUC%extrap) for Lamotrigine Administered without Interacting Drug AG-881

    Time frame: At multiple time points daily from Day 1 to Day 8 in Period 1 (8-day period)

  9. Time to Maximum Observed Plasma Concentration (Tmax) for Lamotrigine Administered with Interacting Drug AG-881

    Time frame: At multiple time points daily from Day 14 to Day 21 (or early discontinuation) in Period 2 (21-day period)

  10. Time to Maximum Observed Plasma Concentration (Tmax) for Lamotrigine Administered without Interacting Drug AG-881

    Time frame: At multiple time points daily from Day 1 to Day 8 in Period 1 (8-day period)

  11. Apparent Terminal Elimination Rate Constant (Kel) for Lamotrigine Administered with Interacting Drug AG-881

    Time frame: At multiple time points daily from Day 14 to Day 21 (or early discontinuation) in Period 2 (21-day period)

  12. Apparent Terminal Elimination Rate Constant (Kel) for Lamotrigine Administered without Interacting Drug AG-881

    Time frame: At multiple time points daily from Day 1 to Day 8 in Period 1 (8-day period)

  13. Apparent Terminal Elimination Half-life (t½) for Lamotrigine Administered with Interacting Drug AG-881

    Time frame: At multiple time points daily from Day 14 to Day 21 (or early discontinuation) in Period 2 (21-day period)

  14. Apparent Terminal Elimination Half-life (t½) for Lamotrigine Administered without Interacting Drug AG-881

    Time frame: At multiple time points daily from Day 1 to Day 8 in Period 1 (8-day period)

  15. Apparent Total Plasma Clearance after Oral (Extravascular) Administration (CL/F) for Lamotrigine Administered with Interacting Drug AG-881

    Time frame: At multiple time points daily from Day 14 to Day 21 (or early discontinuation) in Period 2 (21-day period)

  16. Apparent Total Plasma Clearance after Oral (Extravascular) Administration (CL/F) for Lamotrigine Administered without Interacting Drug AG-881

    Time frame: At multiple time points daily from Day 1 to Day 8 in Period 1 (8-day period)

  17. Apparent Volume of Distribution during the Terminal Elimination Phase after Oral (Extravascular) Administration (Vz/F) for Lamotrigine Administered with Interacting Drug AG-881

    Time frame: At multiple time points daily from Day 14 to Day 21 (or early discontinuation) in Period 2 (21-day period)

  18. Apparent Volume of Distribution during the Terminal Elimination Phase after Oral (Extravascular) Administration (Vz/F) for Lamotrigine Administered without Interacting Drug AG-881

    Time frame: At multiple time points daily from Day 1 to Day 8 in Period 1 (8-day period)

Secondary outcomes

  1. Percentage of Participants with Adverse Events (AEs)

    An AE is any untoward medical occurrence associated with the use of a drug, whether or not considered drug-related.

    Time frame: Up to approximately 4 weeks

  2. Columbia-suicide Severity Rating Scale (C-SSRS)

    The C-SSRS is a questionnaire scale to detect emergent suicide symptoms (suicidal ideation or actual suicidal behavior). Questions are either answered yes/no or are on a scale of 1 (low severity) to 5 (high severity).

    Time frame: Up to approximately 4 weeks

  3. Percentage of Participants with Abnormalities in 12-lead Electrocardiograms (ECGs)

    Time frame: Up to approximately 4 weeks

  4. Percentage of Participants with Abnormalities in Vital Sign Measurements

    Vital signs will include body temperature, respiratory rate, blood pressure, and heart rate.

    Time frame: Up to approximately 4 weeks

  5. Percentage of Participants with Abnormalities in Clinical Laboratory Tests

    Clinical laboratory assessments will include hematology, serum chemistry, coagulation, and urinalysis.

    Time frame: Up to approximately 4 weeks

  6. Percentage of Participants with Abnormalities in Physical Examinations

    Time frame: Up to approximately 4 weeks

07

Study locations

1 site
  • Celerion, Inc
    Tempe, Arizona 85283, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2019 to primary completion in Oct 2019, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2019
First posted
Jul 11, 2019
StartActual
Jul 15, 2019
Primary completionActual
Oct 9, 2019
CompletionActual
Oct 9, 2019
Last update
Oct 14, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 14, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04015687
Responsible party
Sponsor
First posted
Jul 11, 2019
Start date
Jul 15, 2019
Primary completion
Oct 9, 2019
Completion
Oct 9, 2019
Last update
Oct 14, 2019

Study contacts

Medical Affairs
study director · Agios Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Vorasidenib · Lamotrigine

Start the discussion